Progression-Free Survival of a Patient with Advanced Hepatocellular Carcinoma Treated with Adoptive Cell Therapy Using Natural Killer Cells: A Case Report

References

• Park JW, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015;35(9):2155–2166. doi:10.1111/liv.12818
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.21338
   PubMed Web of Science ®Google Scholar
• Parikh ND, Marshall VD, Singal AG, et al. Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: an analysis of the SEER-Medicare database. Hepatology. 2017;65(1):122–133. doi:10.1002/hep.28881
   PubMed Web of Science ®Google Scholar
• Zhu ZX, Huang JW, Liao MH, Zeng Y. Treatment strategy for hepatocellular carcinoma in China: radiofrequency ablation versus liver resection. Jpn J Clin Oncol. 2016;46(12):1075–1080. doi:10.1093/jjco/hyw134
   PubMed Web of Science ®Google Scholar
• Cao J, Kong FH, Liu X, Wang XB. Immunotherapy with dendritic cells and cytokine-induced killer cells for hepatocellular carcinoma: a meta-analysis. World J Gastroenterol. 2019;25(27):3649–3663. doi:10.3748/wjg.v25.i27.3649
   PubMed Web of Science ®Google Scholar
• Comoli P, Chabannon C, Koehl U, et al. Development of adaptive immune effector therapies in solid tumors. Ann Oncol. 2019;30(11):1740–1750. doi:10.1093/annonc/mdz285
   PubMed Web of Science ®Google Scholar
• Vivier E, Raulet DH, Moretta A, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011;331(6013):44–49. doi:10.1126/science.1198687
   PubMed Web of Science ®Google Scholar
• Knorr DA, Bachanova V, Verneris MR, Miller JS. Clinical utility of natural killer cells in cancer therapy and transplantation. Semin Immunol. 2014;26(2):161–172. doi:10.1016/j.smim.2014.02.002
   PubMed Web of Science ®Google Scholar
• Lim O, Lee Y, Chung H, et al. GMP-compliant, large-scale expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells in vitro and in vivo. PLoS One. 2013;8(1):e53611. doi:10.1371/journal.pone.0053611
   PubMed Web of Science ®Google Scholar
• Yang Y, Lim O, Kim TM, et al. Phase I study of random healthy donor-derived allogeneic natural killer cell therapy in patients with malignant lymphoma or advanced solid tumors. Cancer Immunol Res. 2016;4(3):215–224. doi:10.1158/2326-6066.CIR-15-0118
   PubMed Web of Science ®Google Scholar
• Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res. 2011;17(19):6287–6297. doi:10.1158/1078-0432.CCR-11-1347
   PubMed Web of Science ®Google Scholar
• Geller MA, Cooley S, Judson PL, et al. A Phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy. 2011;13(1):98–107. doi:10.3109/14653249.2010.515582
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in Oncology. J Natl Cancer Inst. 1993;85(5):365–376. doi:10.1093/jnci/85.5.365
   PubMed Web of Science ®Google Scholar
• Schut AW, Timbergen MJM, Lidington E, et al. The evaluation of health-related quality of life issues experienced by patients with desmoid-type fibromatosis (the QUALIFIED study)-a protocol for an international cohort study. Cancers. 2021;13(13):3068. doi:10.3390/cancers13133068
   PubMed Web of Science ®Google Scholar
• Witkowski D. EORTC QLQ-C30 Scoring Manual. University of Copenhagen; 2021.
   Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.026
   PubMed Web of Science ®Google Scholar
• Center MM, Jemal A. International trends in liver cancer incidence rates. Cancer Epidemiol Biomarkers Prev. 2011;20(11):2362–2368. doi:10.1158/1055-9965.EPI-11-0643
   PubMed Web of Science ®Google Scholar
• Liu Z, Mao X, Jiang Y, et al. Changing trends in the disease burden of primary liver cancer caused by specific etiologies in China. Cancer Med. 2019;8(12):5787–5799. doi:10.1002/cam4.2477
   PubMed Web of Science ®Google Scholar
• Anwanwan D, Singh SK, Singh S, Saikam V, Singh R. Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer. 2020;1873(1):188314. doi:10.1016/j.bbcan.2019.188314
   PubMed Web of Science ®Google Scholar
• Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–1474. doi:10.1245/s10434-010-0985-4
   PubMed Web of Science ®Google Scholar
• Xie F, Zhang X, Li H, et al. Adoptive immunotherapy in postoperative hepatocellular carcinoma: a systemic review. PLoS One. 2012;7(8):e42879. doi:10.1371/journal.pone.0042879
   PubMed Web of Science ®Google Scholar
• Nguyen R, Wu H, Pounds S, et al. A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia. J Immunother Cancer. 2019;7(1):81. doi:10.1186/s40425-019-0564-6
   PubMed Web of Science ®Google Scholar
• Cooley S, He F, Bachanova V, et al. First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia. Blood Adv. 2019;3(13):1970–1980. doi:10.1182/bloodadvances.2018028332
   PubMed Web of Science ®Google Scholar
• Bachanova V, Sarhan D, DeFor TE, et al. Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells. Cancer Immunol Immunother. 2018;67(3):483–494. doi:10.1007/s00262-017-2100-1
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Okayama T, Sakamoto N, et al. Phase I clinical trial of adoptive transfer of expanded natural killer cells in combination with IgG1 antibody in patients with gastric or colorectal cancer. Int J Cancer. 2018;142(12):2599–2609. doi:10.1002/ijc.31285
   PubMed Web of Science ®Google Scholar
• Shah N, Li L, McCarty J, et al. Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. Br J Haematol. 2017;177(3):457–466. doi:10.1111/bjh.14570
   PubMed Web of Science ®Google Scholar
• Tonn T, Schwabe D, Klingemann HG, et al. Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy. 2013;15(12):1563–1570. doi:10.1016/j.jcyt.2013.06.017
   PubMed Web of Science ®Google Scholar
• Lin M, Liang S, Wang X, et al. Cryoablation combined with allogenic natural killer cell immunotherapy improves the curative effect in patients with advanced hepatocellular cancer. Oncotarget. 2017;8(47):81967–81977. doi:10.18632/oncotarget.17804
   PubMedGoogle Scholar
• Xie S, Wu Z, Zhou L, et al. Iodine-125 seed implantation and allogenic natural killer cell immunotherapy for hepatocellular carcinoma after liver transplantation: a case report. Onco Targets Ther. 2018;11:7345–7352. doi:10.2147/OTT.S166962
   PubMed Web of Science ®Google Scholar
• Hosseinzadeh F, Ai J, Ebrahimi-Barough S, et al. Natural killer cell expansion with autologous feeder layer and Anti-CD3 antibody for immune cell therapy of hepatocellular carcinoma. Asian Pac J Cancer Prev. 2019;20(12):3797–3803. doi:10.31557/APJCP.2019.20.12.3797
   PubMedGoogle Scholar
• Denman CJ, Senyukov VV, Somanchi SS, et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS One. 2012;7(1):e30264. doi:10.1371/journal.pone.0030264
   PubMed Web of Science ®Google Scholar
• Somanchi SS, Lee DA. Ex vivo expansion of human NK cells using K562 engineered to express membrane bound IL21. Methods Mol Biol. 2016;1441:175–193.
   PubMedGoogle Scholar
• Baek H-J, Kim J-S, Yoon M, et al. Ex vivo expansion of natural killer cells using cryopreserved irradiated feeder cells. Anticancer Res. 2013;33(5):2011–2019.
   PubMed Web of Science ®Google Scholar
• Ojo EO, Sharma AA, Liu R, et al. Membrane bound IL-21 based NK cell feeder cells drive robust expansion and metabolic activation of NK cells. Sci Rep. 2019;9(1):14916. doi:10.1038/s41598-019-51287-6
   PubMed Web of Science ®Google Scholar
• Wang X, Lee DA, Wang Y, et al. Membrane-bound interleukin-21 and CD137 ligand induce functional human natural killer cells from peripheral blood mononuclear cells through STAT-3 activation. Clin Exp Immunol. 2013;172(1):104–112. doi:10.1111/cei.12034
   PubMed Web of Science ®Google Scholar
• Streltsova MA, Erokhina SA, Kanevskiy LM, et al. Recurrent stimulation of natural killer cell clones with K562 expressing membrane-bound interleukin-21 affects their phenotype, interferon-gamma production, and lifespan. Int J Mol Sci. 2019;20(2):443. doi:10.3390/ijms20020443
   PubMed Web of Science ®Google Scholar
• Fujisaki H, Kakuda H, Shimasaki N, et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res. 2009;69(9):4010–4017. doi:10.1158/0008-5472.CAN-08-3712
   PubMed Web of Science ®Google Scholar
• Ciurea SO, Schafer JR, Bassett R, et al. Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation. Blood. 2017;130(16):1857–1868. doi:10.1182/blood-2017-05-785659
   PubMed Web of Science ®Google Scholar
• Rochigneux P, Chanez B, De Rauglaudre B, Mitry E, Chabannon C, Gilabert M. Adoptive cell therapy in hepatocellular carcinoma: biological rationale and first results in early phase clinical trials. Cancers. 2021;13(2):271. doi:10.3390/cancers13020271
   PubMed Web of Science ®Google Scholar
• Shi D, Shi Y, Kaseb AO, et al. Chimeric antigen receptor-glypican-3 T-cell therapy for advanced hepatocellular carcinoma: results of phase I trials. Clin Cancer Res. 2020;26(15):3979–3989. doi:10.1158/1078-0432.CCR-19-3259
   PubMed Web of Science ®Google Scholar
• Voskoboinik I, Whisstock JC, Trapani JA. Perforin and granzymes: function, dysfunction and human pathology. Nat Rev Immunol. 2015;15(6):388–400. doi:10.1038/nri3839
   PubMed Web of Science ®Google Scholar
• Kashii Y, Giorda R, Herberman RB, et al. Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells. J Immunol. 1999;163(10):5358–5366.
   PubMed Web of Science ®Google Scholar